Erin Parry, MD, PhD

Erin Parry, MD, PhD

Medical Oncology

Contact Information

Office Phone Number







Erin Parry, MD, PhD

Dr. Parry received her undergraduate degree from Colby College and attended Johns Hopkins University School of Medicine where she earned an MD and a PhD. Upon graduation from medical school, Dr. Parry completed residency training in internal medicine at the Johns Hopkins Hospital followed by medical oncology fellowship at Dana-Farber/Partners CancerCare. During her fellowship, Dr. Parry conducted post-doctoral research in the laboratory of Dr. Catherine Wu on Richter transformation of CLL. Dr. Parry's laboratory currently focuses on the transformation of indolent lymphoma to aggressive lymphoma and mechanisms of immune evasion in lymphoma and CLL.



Instructor in Medicine, Harvard Medical School


Lymphoma Program
Center for Chronic Lymphocytic Lymphoma (CLL)

Board Certification

  • Internal Medicine, 2016
  • Medical Oncology, 2021


  • Dana-Farber/Partners CancerCare, Medical Oncology


  • Johns Hopkins Hospital, Internal Medicine

Medical School

  • Johns Hopkins University School of Medicine


    Dr. Parry's laboratory currently focuses on the transformation of indolent lymphoma to aggressive lymphoma and mechanisms of immune evasion in lymphoma and CLL.


      • A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8(10):2342-2350. View in: Pubmed

      • Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42(17):2071-2079. View in: Pubmed

      • The molecular map of CLL and Richter's syndrome. Semin Hematol. 2024 Apr; 61(2):73-82. View in: Pubmed

      • DLBCL arising from indolent lymphomas: How are they different? Semin Hematol. 2023 Nov; 60(5):277-284. View in: Pubmed

      • A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198. View in: Pubmed

      • ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 10 09; 41(10):1803-1816.e8. View in: Pubmed

      • Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759. View in: Pubmed

      • Richter syndrome: novel insights into the biology of transformation. Blood. 2023 07 06; 142(1):11-22. View in: Pubmed

      • A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. View in: Pubmed

      • In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 03 01; 4(2):150-169. View in: Pubmed

      • Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826. View in: Pubmed

      • Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169. View in: Pubmed

      • Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 04 07; 139(14):2252-2256. View in: Pubmed

      • Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. View in: Pubmed

      • Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063. View in: Pubmed

      • Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021 11 01; 106(11):2845-2852. View in: Pubmed

      • Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. View in: Pubmed

      • Supporting the Next Generation of Scientists to Lead Cancer Immunology Research. Cancer Immunol Res. 2021 11; 9(11):1245-1251. View in: Pubmed

      • Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma. J Thorac Oncol. 2017 11; 12(11):1673-1678. View in: Pubmed

      • Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med. 2016 08 10; 8(351):351ra107. View in: Pubmed

      • Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat. 2013 Nov; 34(11):1481-5. View in: Pubmed

      • Concomitant antibiotic and mercury resistance among gastrointestinal microflora of feral brook trout, Salvelinus fontinalis. Curr Microbiol. 2012 Nov; 65(5):575-82. View in: Pubmed

      • Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):904-12. View in: Pubmed

      • Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011 May 26; 117(21):5607-11. View in: Pubmed

      • Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet. 2011 May; 48(5):327-33. View in: Pubmed

      • Short telomeres compromise ß-cell signaling and survival. PLoS One. 2011 Mar 10; 6(3):e17858. View in: Pubmed

      • Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet. 2009 Dec; 85(6):823-32. View in: Pubmed

      • Transferable, multiple antibiotic and mercury resistance in Atlantic Canadian isolates of Aeromonas salmonicida subsp. salmonicida is associated with carriage of an IncA/C plasmid similar to the Salmonella enterica plasmid pSN254. J Antimicrob Chemother. 2008 Jun; 61(6):1221-8. View in: Pubmed

      • An 11-amino acid beta-hairpin loop in the cytoplasmic domain of band 3 is responsible for ankyrin binding in mouse erythrocytes. Proc Natl Acad Sci U S A. 2007 Aug 28; 104(35):13972-7. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Erin Parry, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block